Literature DB >> 17094098

Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy.

Victoria Heldestad1, Erik Nordh.   

Abstract

Transthyretin amyloid neuropathy of type 1 (Swedish-Portuguese type) is an autosomally inherited progressive disease with a Val30Met mutation, causing generalized sensory-motor polyneuropathy. Quantitative sensory testing (QST) quantifies thermal threshold changes in patients with manifest general polyneuropathy, but its applicability at an early clinical stage of a strict biochemically defined disease has not yet been shown. Thermal QST was performed in 23 patients having a positive Val30Met marker and clinical symptoms of peripheral small-fiber neuropathy but normal electrophysiological findings and compared to a reference group of 43 healthy volunteers, both subdivided into age groups < or =45 and >45 years. Significant differences between patients and controls were found at all test sites in both age groups, except for warm thresholds at the medial lower leg in those >45 years. QST thus demonstrated elevated thermal thresholds before the development of electrophysiological abnormalities, which indicate large-fiber involvement. These findings confirm that QST is a useful method for documentation of developing polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17094098     DOI: 10.1002/mus.20689

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.

Authors:  Philippe Kerschen; Violaine Planté-Bordeneuve
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

3.  Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Wouter Wieling; Frits A Wijburg; Carla E M Hollak
Journal:  BMC Neurol       Date:  2010-06-07       Impact factor: 2.474

4.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

5.  Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.

Authors:  Jean-Pascal Lefaucheur; Sophie Ng Wing Tin; Philippe Kerschen; Thibaud Damy; Violaine Planté-Bordeneuve
Journal:  J Neurol       Date:  2013-01-11       Impact factor: 4.849

6.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

7.  Thermal perception thresholds among workers in a cold climate.

Authors:  Lage Burström; Bodil Björ; Tohr Nilsson; Hans Pettersson; Ingemar Rödin; Jens Wahlström
Journal:  Int Arch Occup Environ Health       Date:  2017-05-11       Impact factor: 3.015

8.  Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.

Authors:  Fabiola Escolano-Lozano; Ana Paula Barreiros; Frank Birklein; Christian Geber
Journal:  Brain Behav       Date:  2017-12-19       Impact factor: 2.708

9.  Method-of-limits; Cold and warm perception thresholds at proximal and distal body regions.

Authors:  Victoria Heldestad Lilliesköld; Erik Nordh
Journal:  Clin Neurophysiol Pract       Date:  2018-07-05

10.  Neurosensory sequelae assessed by thermal and vibrotactile perception thresholds after local cold injury.

Authors:  Daniel Carlsson; Lage Burström; Victoria Heldestad Lilliesköld; Tohr Nilsson; Erik Nordh; Jens Wahlström
Journal:  Int J Circumpolar Health       Date:  2014-02-17       Impact factor: 1.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.